K2 HealthVentures

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Evergreen Nephrology focuses on enhancing kidney care for patients suffering from kidney disease by supporting nephrologists with strategic partnerships and comprehensive resources. The organization aims to improve patient experiences by providing interdisciplinary clinical support, analytical insights, and necessary services. Their approach emphasizes delaying disease progression, facilitating home-based kidney care, and ensuring timely access to organ transplants and dialysis. By empowering nephrologists with financial backing and tools, Evergreen Nephrology seeks to transform kidney care, ultimately improving patient quality of life and increasing healthy days at home.

HarmonyCares specializes in delivering comprehensive medical care directly to clients in their homes. The company focuses on individuals with multiple chronic conditions, cognitive challenges, and psychosocial issues, offering a range of services that include primary and specialty care programs, home health services, hospice and palliative care, as well as diagnostic services such as radiology and laboratory testing. By providing high-quality, integrated care in a comfortable setting, HarmonyCares aims to meet the diverse health needs of patients, particularly the elderly, while also supplying durable medical equipment to enhance their home care experience. Rebranded from U.S. Medical Management in 2022, HarmonyCares emphasizes a physician-driven approach to ensure optimal health outcomes for its clients.

Operator of a data-driven healthcare startup intended to transform healthcare in rural communities through exceptional care, bringing better access and quality service to its patients. The company delivers tailored quality care through a team-based model, with resources and support for patients, inside and outside clinics, thereby enabling healthcare professionals to provide the support and care that patients need.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Livermore, California, focused on discovering and developing therapeutics and diagnostics for Alzheimer's disease and related neurodegenerative conditions. The company is advancing a targeted immunotherapy drug candidate, ACU193, which selectively targets amyloid-beta oligomers, believed to be a significant contributor to the disease process. Acumen employs a sensitivity assay to measure soluble amyloid-beta oligomer levels in cerebrospinal fluid, which aids in patient enrollment for clinical trials. The Phase 1 clinical trial for ACU193, initiated in the second quarter of 2021, aims to evaluate the drug's safety, tolerability, pharmacokinetics, and target engagement among patients with mild cognitive impairment and mild dementia due to Alzheimer's disease. Results from this trial are anticipated by the end of 2022. Founded in 1996, Acumen Pharmaceuticals is committed to developing innovative approaches to address the challenges posed by Alzheimer's disease.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

89bio, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, dedicated to developing therapies for liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) designed for the treatment of nonalcoholic steatohepatitis (NASH). This therapy is engineered to address key liver pathologies, including steatosis and fibrosis, as well as underlying metabolic dysregulation associated with NASH. Additionally, 89bio is expanding the potential applications of BIO89-100 to include the treatment of severe hypertriglyceridemia. Founded in 2018, 89bio aims to advance its innovative therapies through clinical development to meet significant unmet medical needs.

LetsGetChecked is an at-home health testing platform that connects customers with regulated laboratory testing, enabling individuals to manage their health effectively. Based in New York, the company offers a wide range of testing kits for general wellness, sexual health, women's health, men's health, and specific illnesses, including cancer and fertility issues. Users can order testing kits online, collect samples such as blood or urine, and return them using prepaid envelopes. The analyzed results are then uploaded online, providing customers with convenient access to their health information. LetsGetChecked operates nationwide in the United States and extends its services to Canada and Europe, promoting a patient-led approach to healthcare through technology.

Alignment Health is a healthcare organization focused on providing tailored care solutions for seniors, primarily through Medicare Advantage plans. By offering a consumer-centric platform, it allows seniors to choose their healthcare coverage and services annually. The company emphasizes a combination of technology and clinical coordination to enhance health outcomes, facilitating care through various channels, including phone, online, and in-person settings. Additionally, Alignment Health supports its partners and patients with risk management and customized services, ensuring a comprehensive approach to healthcare delivery.

Operator of a data-driven healthcare startup intended to transform healthcare in rural communities through exceptional care, bringing better access and quality service to its patients. The company delivers tailored quality care through a team-based model, with resources and support for patients, inside and outside clinics, thereby enabling healthcare professionals to provide the support and care that patients need.

Dialyze Direct is a healthcare company provides staff assisted home hemodialysis services to elderly patients with End Stage Renal Disease.

Longevity Health Plan is a healthcare company focused on providing personalized clinical care and therapy services specifically for the elderly. The organization offers a range of services that include preventive screenings for vision, hearing, and foot care. By employing an integrated team of rehabilitative therapists, Longevity Health Plan aims to coordinate care effectively, which helps in reducing avoidable hospitalizations among its members, particularly those in institutional settings. The company's commitment to tailored healthcare solutions addresses the unique needs of older adults, promoting their overall well-being and health management.

DispatchHealth Management, LLC specializes in on-demand mobile and virtual healthcare services, aimed at delivering quality care directly to patients in their homes. Founded in 2013 and based in Denver, Colorado, the company provides a wide range of medical services, including evaluations for acute injuries and illnesses, laceration repairs, splinting, and treatment for conditions such as nosebleeds. Additionally, DispatchHealth offers vital medical procedures like Foley catheter and G-tube placements, medication administration, laboratory testing, and outpatient imaging arrangements. With a focus on convenience and integration, the company enhances the capabilities of patients' care teams while striving to reduce healthcare costs.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company’s flagship product, Sci-B-Vac, is a commercial-stage hepatitis B vaccine that effectively mimics all three viral surface antigens, providing rapid protection and high antibody levels with lower dosing requirements compared to traditional vaccines. VBI's innovative enveloped virus-like particle (eVLP) platform technology facilitates the creation of vaccines that closely resemble target viruses, enhancing immune responses. The company is advancing several clinical programs, including VBI-1901, an immunotherapeutic candidate for glioblastoma, and VBI-1501, a prophylactic vaccine for cytomegalovirus. VBI collaborates with various organizations, including Brii Biosciences and GlaxoSmithKline, and partners with the National Research Council of Canada to develop a pan-coronavirus vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. aims to address unmet medical needs through its innovative vaccine solutions.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.

Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

OncXerna Therapeutics develops precision medicines for cancer patients by utilizing an innovative RNA-based biomarker platform that identifies patient responses based on the biology of their tumor microenvironments. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, the company aims to enhance patient care by matching individuals with clinical-stage therapies that specifically target their unique cancer biology. This approach allows OncXerna to provide potentially first-in-class oncology therapies, significantly improving patient outcomes. The company was previously known as Oncologie, Inc. before rebranding in September 2020.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical use. Founded in 2014, the company has developed a microfluidic bioreactor designed to generate functional platelets from human stem cell cultures at a commercial scale. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing a vital resource for patients worldwide. The company is also focused on advancing therapeutics within the fields of biotechnology and drug discovery.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Invaio Sciences, Inc. is a technology company based in Cambridge, Massachusetts, with additional locations in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Founded in 2016, the company focuses on harnessing the potential of interdependent natural systems to address significant challenges in agriculture, nutrition, and the environment. Invaio Sciences is dedicated to developing innovative technologies grounded in scientific research, aiming to implement transformative solutions that positively impact agriculture, human health, animal nutrition, and animal health.

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Cricket Health Inc. is a specialty kidney care provider that focuses on delivering integrated nephrology and dialysis services for individuals with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Founded in 2015 and based in San Francisco, the company employs a technology-enabled, multidisciplinary approach to patient care, offering both in-person and virtual services. Cricket Health aims to enhance patient outcomes while providing value to healthcare partners by prioritizing patient health, reducing hospitalizations, facilitating access to transplants, and promoting home dialysis adoption. The company is dedicated to identifying at-risk patients early, managing disease progression, and delivering personalized care options such as transplant support and various dialysis modalities.

ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Singapore, focusing on developing innovative treatments in the fields of immunology and oncology. Founded in 2010, the company is dedicated to transforming the lives of patients through its clinical portfolio, which includes ASLAN004, a monoclonal therapy aimed at treating atopic dermatitis and other immunological conditions, as well as a small molecule inhibitor directed at oncology applications. ASLAN collaborates with several partners, enhancing its research and development efforts.

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company’s flagship product, Sci-B-Vac, is a commercial-stage hepatitis B vaccine that effectively mimics all three viral surface antigens, providing rapid protection and high antibody levels with lower dosing requirements compared to traditional vaccines. VBI's innovative enveloped virus-like particle (eVLP) platform technology facilitates the creation of vaccines that closely resemble target viruses, enhancing immune responses. The company is advancing several clinical programs, including VBI-1901, an immunotherapeutic candidate for glioblastoma, and VBI-1501, a prophylactic vaccine for cytomegalovirus. VBI collaborates with various organizations, including Brii Biosciences and GlaxoSmithKline, and partners with the National Research Council of Canada to develop a pan-coronavirus vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. aims to address unmet medical needs through its innovative vaccine solutions.

Vesta Healthcare is a technology and clinical services organization that focuses on enhancing the connection between caregivers and the broader care team. The company provides 24/7 telehealth support for caregivers and care recipients, particularly targeting high-need, frail senior populations. By partnering with home care agencies, health plans, and healthcare providers, Vesta Healthcare develops value-based population health programs that prioritize clinical quality, improved health outcomes, and personalized engagement. Originally established as Hometeam Technologies, Inc. in 2008, the company rebranded to Vesta Healthcare in January 2020 and is headquartered in New York, New York.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Colorescience, Inc. is a skincare brand based in Carlsbad, California, specializing in mineral-based cosmetics and sunscreen products. Founded in 2000, the company offers a range of items, including treatment products, UV protectors, primers, foundations, and enhancers, designed to address various skin concerns such as pigmentation, redness, dark circles, and signs of aging. Colorescience emphasizes high-quality, dermatologist-recommended formulations that incorporate minerals, antioxidants, and botanicals to promote healthy skin and protect against sun damage. The brand markets its products through a network of licensed physicians, luxury spas, retailers, and online platforms, aiming to stand out in the aesthetic makeup segment by providing effective and easy-to-use solutions for diverse skin types.

Corbus Pharmaceuticals is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, that focuses on developing and commercializing therapeutics for inflammatory and fibrotic diseases. Founded in 2009, the company’s lead product candidate, lenabasum, is a synthetic oral CB2 agonist currently undergoing Phase III clinical trials for systemic sclerosis and dermatomyositis, and Phase IIb trials for systemic lupus erythematosus and cystic fibrosis. In addition to lenabasum, Corbus is developing CRB-4001, a peripherally-restricted CB1 inverse agonist aimed at treating nonalcoholic steatohepatitis and other fibrotic conditions. The company is leveraging a diverse pipeline of drug candidates sourced from a library of over 600 novel compounds targeting the endocannabinoid system. Furthermore, Corbus has established collaborations for the development and commercialization of its products, including a partnership with Kaken Pharmaceutical Co., Ltd. for lenabasum in Japan.

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company’s flagship product, Sci-B-Vac, is a commercial-stage hepatitis B vaccine that effectively mimics all three viral surface antigens, providing rapid protection and high antibody levels with lower dosing requirements compared to traditional vaccines. VBI's innovative enveloped virus-like particle (eVLP) platform technology facilitates the creation of vaccines that closely resemble target viruses, enhancing immune responses. The company is advancing several clinical programs, including VBI-1901, an immunotherapeutic candidate for glioblastoma, and VBI-1501, a prophylactic vaccine for cytomegalovirus. VBI collaborates with various organizations, including Brii Biosciences and GlaxoSmithKline, and partners with the National Research Council of Canada to develop a pan-coronavirus vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. aims to address unmet medical needs through its innovative vaccine solutions.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.

Companion Medical, Inc. is a company focused on enhancing diabetes management through innovative medical technology. Based in San Diego, California, it develops the InPen, a smart insulin delivery system that integrates a wireless insulin pen with a mobile application. This system calculates and recommends optimal insulin dosing, tracks injection history and timing, monitors insulin temperature, and keeps patients informed about their last dose and remaining insulin. The InPen's features allow users to report their data to healthcare providers, facilitating better management of their condition. Incorporated in 2013, Companion Medical operates as a subsidiary of Medtronic plc, leveraging its expertise in medical devices to improve patient care for those who rely on insulin.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies. The company specializes in creating human immunoglobulin isotype G4 monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, which targets CD73; SRF617, which inhibits CD39; SRF388, aimed at interleukin 27; and SRF813, which targets CD112R. Additionally, Surface Oncology is advancing several preclinical programs that address other critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established strategic collaborations with Novartis Institutes for Biomedical Research and Merck Sharp & Dohme Corp. to advance the development of its therapies, including evaluating the combination of SRF617 with Merck’s KEYTRUDA. Founded in 2014, Surface Oncology aims to leverage novel immunotherapy targets and insights into cancer immuno-biology to enhance anti-tumor immune responses.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Evelo Biosciences is a biotechnology company focused on discovering and developing oral biologics known as monoclonal microbials for the treatment of inflammatory diseases and cancer. These innovative medicines are designed to modulate systemic immunology through direct interactions with human cells in the gut, offering potential applications across a wide range of conditions, including autoimmune and neuroinflammatory diseases, as well as various cancers. Evelo's lead product, EDP1815, is currently undergoing clinical trials for psoriasis and atopic dermatitis, while other candidates are in preclinical stages for conditions such as psoriatic arthritis, asthma, and colorectal cancer. Founded in 2014 and based in Cambridge, Massachusetts, Evelo aims to enhance the efficiency and effectiveness of drug discovery by leveraging naturally occurring microbial entities with defined therapeutic effects.

Spark Pediatrics operates a chain of medical daycare facilities dedicated to addressing the medical, therapeutic, developmental, and social needs of children, particularly those with special requirements. The organization offers skilled nursing care and a range of therapy services, including physical, occupational, and speech therapies, within a supportive and engaging environment. By collaborating closely with patients, families, physicians, and referral sources, Spark Pediatrics ensures that each child receives tailored treatment plans designed to foster their growth and well-being. The focus remains on providing professional and compassionate care that meets the unique needs of every child served.